In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thar Pharmaceuticals Inc.

Division of Grunenthal GmbH
www.tharpharma.com

Latest From Thar Pharmaceuticals Inc.

Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore

The latest drug development news and highlights from our FDA Performance Tracker.

Regulation Approvals

Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals

Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Thar Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Grunenthal GmbH
  • Senior Management
  • Raymond K Houck, CEO
    Ira Kalfus, MD, CMO
    Jason Bablak, VP, Reg. Affairs
    Mazen Hanna, PhD, CSO
    Brian Moyer, SVP, Corp. Dev. & Fin.
  • Contact Info
  • Thar Pharmaceuticals Inc.
    Phone: (412) 963-6800
    150 Gamma Dr.
    Pittsburgh, PA 15238
    USA
UsernamePublicRestriction

Register